~ Melatonin Slows Cancer But Is Little Used

PR Newswire, 07-29-05

WESTON, Mass., July 28, 2005 /PRNewswire via COMTEX/ -- Despite growing evidence that melatonin significantly improves risk, survival, and performance status in patients with advanced cancer, it continues to be overlooked as a therapeutic option because it lacks US Food and Drug Administration (FDA) approval and requires administration at times of day inconvenient to physicians.

Fade Mahmoud, MD, of the University of South Dakota at Sioux Falls, and colleagues conducted a review of the literature from 1990 to 2004 to assess the benefits of melatonin, a hormone secreted by the pineal gland, as supported by clinical research. Their findings appear in the July/August 2005 issue of American Journal of Hospice & Palliative Medicine.

Mahmoud's team found strong evidence supporting melatonin's role as an antitumor agent. Melatonin is a chronobiotic; that is, it has the ability to set and reset the body's circadian clock. Cancer cell proliferation peaks at certain points in a 24-hour period. As a chemical regulator of the circadian clock, melatonin slows cancer growth if administered when cell proliferation is expected to be high.

Despite the evidence, few physicians incorporate chronotherapy in their clinical practice. Anticancer therapies continue to be scheduled according to physician convenience rather than for maximum efficacy. In addition, because the hormone is not yet regulated by the FDA, the debate regarding the purity, safety, and efficacy of over-the-counter melatonin continues.

The authors conclude that regulated melatonin is an effective treatment for advanced cancer and call for further research to determine optimal dose and administration time to maximize its clinical effects.

To subscribe, visit the Journal's Web site at http://www.hospicejournal.com. The article abstract can be accessed online at http://www.pnpco.com/mahmoud.html. For additional information, contact the publisher at American Journal of Hospice & Palliative Medicine, 470 Boston Post Road, Weston, MA 02493, Tel. 781-899-2702 x142.

Contact:

Richard DeVito, Sr., Publisher

Phone: 781-899-2702 x142

radsr@pnpco.com

SOURCE American Journal of Hospice & Palliative Medicine

CONTACT: Richard DeVito, Sr., Publisher of American Journal of Hospice & Palliative

Medicine, +1-781-899-2702 ext 142, radsr@pnpco.com

URL: http://www.prnewswire.com

http://www.hospicejournal.com

http://www.pnpco.com/mahmoud.html www.prnewswire.com


Free Shipping in the Continental U.S. on Orders over $50
The statements made here have not been evaluated by the FDA. The foregoing statements are based upon sound and reliable studies, and are meant for informational purposes. Consult with your medical practitioner to determine the underlying cause of your symptoms. Please always check your purchase for possible allergins and correct dosage on the bottle before use.

While we work to ensure that product information is correct, on occasion manufacturers may alter their ingredient lists. Actual product packaging and materials may contain more and/or different information than that shown on our Web site. We recommend that you do not solely rely on the information presented and that you always read labels, warnings, and directions before using or consuming a product. For additional information about a product, please contact the manufacturer. Content on this site is for reference purposes and is not intended to substitute for advice given by a physician, pharmacist, or other licensed health-care professional. You should not use this information as self-diagnosis or for treating a health problem or disease. Contact your health-care provider immediately if you suspect that you have a medical problem. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease or health condition. Life Ex Online assumes no liability for inaccuracies or misstatements about products.